Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial

Gottlieb, Alice B., Mease, Philip, McInnes, Iain B., Kirkham, Bruce, Kavanaugh, Arthur, Rahman, Proton, Nash, Peter, Pricop, Luminita, Yuan, Jiacheng, Richards, Hanno and Mpofu, Shephard (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial. In: Arthritis & Rheumatology. , , (S233-S233). .

Author Gottlieb, Alice B.
Mease, Philip
McInnes, Iain B.
Kirkham, Bruce
Kavanaugh, Arthur
Rahman, Proton
Nash, Peter
Pricop, Luminita
Yuan, Jiacheng
Richards, Hanno
Mpofu, Shephard
Title of paper Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
Proceedings title Arthritis & Rheumatology   Check publisher's open access policy
Journal name Arthritis   Check publisher's open access policy
Publication Year 2014
Sub-type Published abstract
ISSN 2326-5191
Volume 66
Start page S233
End page S233
Total pages 1
Language eng
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Conference Paper
Collection: WoS Import
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 15 Feb 2015, 00:45:40 EST by System User